Changes in China Spark More External Oncology Drug Investments

Posted by Matt Furlow on Feb 19, 2020 8:00:00 AM

Bas Ludoph, Sonia Yan, Kelly Wang and Hannah Wang co-authored this post with Matt Furlow. 

China has become the world’s second largest pharmaceutical market (the US is No. 1), but novel drugs contribute to just a small fraction of that marketWhile there's great potential in China for novel drugsespecially those developed to treat cancer—it has  historically been a challenging market due to a difficult drug approval process, stringent market access policies and a complex healthcare ecosystem. Those factors have shifted over time and made China more amenable to external investmentsparticularly for novel oncology therapies.

Read More